Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2023-04-20 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
关于举办2022年年度报告网上业绩说明会的通知公告
AGM Information Classification · 95% confidence The document is a notice announcing the holding of an online performance explanation meeting related to the 2022 annual report. It mentions the approval and publication of the 2022 annual report but does not contain the report itself or detailed financial data. The document invites investors to participate in the meeting and submit questions. The length is short (829 characters), and it serves as an announcement rather than the report or transcript itself. Therefore, it fits the category of AGM Information (AGM-R), as it relates to materials shared during an annual meeting or performance explanation session.
2023-04-20 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2022 年年度报告全文" which translates to "2022 Annual Report Full Text" for 嘉事堂药业股份有限公司 (Cachet Pharmaceutical Co., Ltd.). It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, corporate governance, social responsibility, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial data, management commentary, and comprehensive disclosures for the fiscal year 2022. Therefore, this document fits the definition of an Annual Report (10-K).
2023-04-20 Chinese
2022年社会责任报告
Environmental & Social Information Classification · 95% confidence The document is titled '2022 年企业社会责任报告' which translates to '2022 Corporate Social Responsibility Report'. It extensively discusses the company's activities and performance related to social responsibility, including environmental, social, and governance aspects. The content includes sections on company governance, internal control, employee rights, quality management, customer rights, and social welfare activities. There is no indication that this is an annual financial report or an earnings release. The focus on social responsibility and ESG factors aligns with the definition of Environmental & Social Information (SR). The document length is substantial (over 11,000 characters) and contains detailed narrative and data on social responsibility, not just an announcement or summary, so it is not a report publication announcement or regulatory filing. Therefore, the appropriate classification is Environmental & Social Information (SR).
2023-04-20 Chinese
独立董事2022年度述职报告(张海燕)
Board/Management Information Classification · 95% confidence The document is titled 'Independent Director 2022 Annual Work Report' and is a detailed report by an independent director about their duties, attendance at meetings, opinions, investigations, committee roles, and efforts to protect investor rights during the year 2022. It is a narrative report on governance and oversight activities rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or a proxy solicitation. The content aligns with a management or board-related report focusing on governance and director duties. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length is 2257 characters, which is consistent with a detailed report but not a full annual report or earnings release. Confidence is high given the clear focus on independent director duties and governance.
2023-04-20 Chinese
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as a 2022 annual report summary for 嘉事堂药业股份有限公司, containing detailed financial data for the year 2022, including total assets, net profit, revenue, quarterly financial data, shareholder information, and dividend distribution plans. It includes comprehensive financial performance and business overview for the full fiscal year. The document length is 3859 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. The content matches the characteristics of an Annual Report summary rather than a mere announcement or a regulatory filing. Therefore, it should be classified as an Annual Report (10-K).
2023-04-20 Chinese
监事会2022年度工作报告
Management Reports Classification · 95% confidence The document is titled as the Supervisory Board's 2022 Annual Work Report for 嘉事堂药业股份有限公司. It details the supervisory board's activities, meetings held during the year, oversight of financial and operational matters, and opinions on the company's compliance and financial reporting. It references the 2022 Annual Report and the audit report issued by the accounting firm, but the document itself is a supervisory board report summarizing oversight and opinions rather than the full annual report or audit report. The content is a detailed management oversight report rather than a financial statement or audit report. Therefore, it fits best under Management Reports (MDA), which cover management's detailed explanation of financial results, business trends, and outlook, including supervisory board opinions and oversight.
2023-04-20 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.